Oral Health was Haleon’s largest revenue line in fiscal 2025, bringing in $3.46B of $11.03B (31%).
| Products and services [axis] | FY 2021 | FY 2024 | FY 2025 |
|---|---|---|---|
| Oral Health | $3.31B | $3.46B | |
| Pain Relief | $2.56B | $2.56B | |
| Digestive Health & Other | — | — | |
| Respiratory Health | $2.12B | $1.87B | |
| Vitamins, Minerals & Supplements | $1.70B | $1.69B | |
| Digestive Health | $1.03B | $987.00M | |
| Therapeutic Skin Health & Other | $510.00M | $460.00M | |
| Total | $11.23B | $11.03B |
Haleon brought in $11.03B from its six revenue lines in fiscal 2025, the year ended December 31, 2025. That was down 1.8% from $11.23B in fiscal 2024. Oral Health was the largest at $3.46B (31.4%), ahead of Pain Relief at $2.56B (23.2%) and Respiratory Health at $1.87B (17.0%). The other three revenue lines brought in $3.13B combined.
Compared with fiscal 2024, Oral Health grew fastest, up 4.5% to $3.46B, while Respiratory Health fell the most, down 11.7% to $1.87B.
Rest Of World was Haleon’s largest region in fiscal 2025, bringing in $6.19B of $11.03B (56%).
| Markets of customers [axis] | FY 2024 | FY 2025 |
|---|---|---|
| Rest Of World | $6.25B | $6.19B |
| Us | $3.62B | $3.47B |
| China | $987.00M | $999.00M |
| Uk | $384.00M | $374.00M |
| Total | $11.23B | $11.03B |
Haleon brought in $11.03B from its four regions in fiscal 2025, the year ended December 31, 2025. That was down 1.8% from $11.23B in fiscal 2024. Rest Of World was the largest at $6.19B (56.1%), ahead of Us at $3.47B (31.4%) and China at $999.00M (9.1%). The remaining region, Uk, brought in $374.00M.
Compared with fiscal 2024, China grew fastest, up 1.2% to $999.00M, while Us fell the most, down 4.1% to $3.47B.
Emea &Amp; Latam was Haleon’s largest segment in fiscal 2025, bringing in $4.59B of $11.03B (42%).
| Segments [axis] | FY 2021 | FY 2024 | FY 2025 |
|---|---|---|---|
| Emea &Amp; Latam | $4.63B | $4.59B | |
| North America | $4.04B | $3.87B | |
| Apac | $2.56B | $2.57B | |
| Total | $11.23B | $11.03B |
Haleon brought in $11.03B from its three segments in fiscal 2025, the year ended December 31, 2025. That was down 1.8% from $11.23B in fiscal 2024. Emea &Amp; Latam was the largest at $4.59B (41.6%), ahead of North America at $3.87B (35.0%) and Apac at $2.57B (23.3%).
Compared with fiscal 2024, Apac grew fastest, up 0.5% to $2.57B, while North America fell the most, down 4.4% to $3.87B.
Haleon (HLN) reports its revenue by products and services [axis], by markets of customers [axis] and by segments [axis]. In fiscal 2025, Oral Health was its largest revenue line, bringing in $3.46B (31.4% of the total), followed by Pain Relief at $2.56B (23.2%).
Oral Health was Haleon's largest revenue line in fiscal 2025, bringing in $3.46B, or 31.4% of the $11.03B total across its six revenue lines.
Rest Of World was Haleon's largest region in fiscal 2025, bringing in $6.19B, or 56.1% of the $11.03B total across its four regions.
Emea &Amp; Latam was Haleon's largest segment in fiscal 2025, bringing in $4.59B, or 41.6% of the $11.03B total across its three segments.
Among Haleon's revenue lines that make up at least 2% of revenue, Oral Health grew fastest in fiscal 2025, up 4.5% from $3.31B to $3.46B.
Every figure comes from Haleon's annual financial filings, as reported. Each line keeps the name Haleon gives it, and years follow its fiscal calendar.
Haleon's revenue by products and services [axis] goes back to fiscal 2021, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.